SGHT250117C5000
- 0.20
- 0.000.00%
Sight Sciences Newsroom
Lake Street Maintains Sight Sciences(SGHT.US) With Hold Rating, Maintains Target Price $5
Lake Street Issues a Hold Rating on Sight Sciences (SGHT)
Sight Sciences Is Maintained at Neutral by Citigroup
Citi Maintains Sight Sciences(SGHT.US) With Hold Rating, Cuts Target Price to $4.6
Sight Sciences Analyst Ratings
UBS Initiates Sight Sciences(SGHT.US) With Buy Rating, Announces Target Price $5.5
Morgan Stanley Initiates Sight Sciences(SGHT.US) With Hold Rating, Announces Target Price $4
Stifel Maintains Sight Sciences(SGHT.US) With Buy Rating, Cuts Target Price to $6
Stifel Nicolaus Sticks to Its Buy Rating for Sight Sciences (SGHT)
Morgan Stanley Maintains Sight Sciences(SGHT.US) With Hold Rating, Cuts Target Price to $5
Sight Sciences Is Maintained at Equal-Weight by Morgan Stanley
Sight Sciences Analyst Ratings
Piper Sandler Maintains Sight Sciences(SGHT.US) With Hold Rating, Cuts Target Price to $5.5
Lake Street Downgrades Sight Sciences(SGHT.US) to Hold Rating, Cuts Target Price to $5
Piper Sandler Reiterates Neutral on Sight Sciences, Lowers Price Target to $5.5
Morgan Stanley Maintains Sight Sciences(SGHT.US) With Hold Rating, Maintains Target Price $7
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT) and Rocket Pharmaceuticals (RCKT)
Needham Maintains Sight Sciences(SGHT.US) With Hold Rating
Sight Sciences Analyst Ratings
Lake Street Maintains Sight Sciences(SGHT.US) With Buy Rating, Maintains Target Price $10